long intergenic non-protein coding RNA 2765Genealiases: []
Q-omics provides the consensus-scored LINC02765 profile across patient tissues and cancer cell-line models. LINC02765 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02765 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC02765 RNA expression shows 10,824 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where LINC02765 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02765 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02765 survival associations across molecular data types. LINC02765 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02765 RNA expression–survival associations across cancer types. High LINC02765 expression shows unfavorable associations in BLCA, COAD, MESO and ACC, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02765 RNA expression.
This table summarizes LINC02765 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02765. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02765 shows lower tumor expression in BLCA, THCA, KICH, BRCA and READ and higher tumor expression in KIRC. The KIRC box plot shows higher LINC02765 RNA expression in tumor versus normal tissue (log2 FC = +0.315, t-test p < 0.001).
This table shows molecular features associated with LINC02765 in patient tissues and cancer cell lines. In patient samples, LINC02765 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
